keyword
MENU ▼
Read by QxMD icon Read
search

Hematopoietic stem cell transplant

keyword
https://www.readbyqxmd.com/read/28445013/comparison-of-two-apheresis-systems-of-cobe-and-optia-for-autologous-peripheral-blood-stem-cell-collection
#1
Se Na Lee, Ji Yeon Sohn, Jung Hee Kong, Hyeon Seok Eom, Hyewon Lee, Sun Young Kong
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23-66 yr)...
July 2017: Annals of Laboratory Medicine
https://www.readbyqxmd.com/read/28443307/complete-durable-remission-of-a-fulminant-primary-cutaneous-aggressive-epidermotropic-cd8-cytotoxic-t-cell-lymphoma-after-autologous-and-allogeneic-hematopoietic-stem-cell-transplantation
#2
Kerasia-Maria Plachouri, Carsten Weishaupt, Dieter Metze, Georg Evers, Wolfgang E Berdel, Werner Kempf, Cord Sunderkötter, Matthias Stelljes
No abstract text is available yet for this article.
May 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28440401/relationship-between-t-cell-receptor-beta-chain-sequences-and-human-cytomegalovirus-infection-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#3
Zhihua Wu, Huiping Zhang, Min Jin, Hanying Liang, Yaping Huang, Rong Yang, Genyong Gui, Huiqi Wang, Shengnan Gong, Jindong Wang, Jun Fan
In the present study, clonal amplifications of T-cell receptor β variable (TCR BV) linked to human cytomegalovirus (HCMV) infection were detected in recipients of allogeneic hematopoietic stem cell transplants (HSCT), and certain relationships between them were identified. Furthermore, the relationship between TCR BV sequences and HCMV infections was investigated. The results indicated that the 3 recipients of HSCT had monoclonal expansion of specific TCR BV clones following HSCT. Among these recipients, 2 suffered from pp65 and immediate early (IE) antigenemia...
April 11, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28439910/abo-incompatibility-in-mismatched-unrelated-donor-allogeneic-hematopoietic-cell-transplantation-for-acute-myeloid-leukemia-a-report-from-the-acute-leukemia-working-party-of-the-ebmt
#4
Jonathan Canaani, Bipin N Savani, Myriam Labopin, Mauricette Michallet, Charles Craddock, Gerard Socié, Lisa Volin, Johan A Maertens, Charles Crawley, Didier Blaise, Per T Ljungman, Jan Cornelissen, Nigel Russell, Frédéric Baron, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Arnon Nagler
ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs...
April 25, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28439725/nutritional-status-of-allogeneic-hematopoietic-stem-cell-transplantation-recipients-influencing-risk-factors-and-impact-on-survival
#5
Amro Mohamed Sedky El-Ghammaz, Rima Ben Matoug, Maha Elzimaity, Nevine Mostafa
PURPOSE: Patients subjected to allogeneic hematopoietic stem cell transplantation (HSCT) are at increased nutritional risk which in turn may alter their outcome. For providing good nutritional care for patients, it is important to analyze risk factors influencing nutritional status during and after HSCT. METHODS: Fifty patients undergoing allogeneic HSCT were subjected to nutritional status assessment by using the patient-generated subjective global assessment (PG-SGA) at initial admission, day 30 and day 180...
April 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28439700/filgrastim-alone-versus-pegylated-filgrastim-alone-for-autologous-peripheral-blood-stem-cells-mobilization-in-newly-diagnosed-multiple-myeloma-patients
#6
Barbara Skopec, Matevz Skerget, Darja Zontar, Vesna Zadnik, Samo Zver
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) is the recommended standard upfront treatment for transplant eligible myeloma patients. Considering possible complications related to chemotherapy-cytokine mobilization, cytokine-alone mobilization is often used. We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myeloma patients after induction treatment with bortezomib and dexamethasone. The comparison was made between peripheral blood stem cell (PBSC) yields, number of apheresis, hematopoietic stem cell subsets, and time to neutrophil and platelet engraftment after aHSCT...
April 24, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28438889/fda-approval-summary-nivolumab-for-the-treatment-of-relapsed-or-progressive-classical-hodgkin-lymphoma
#7
Yvette L Kasamon, R Angelo de Claro, Yaping Wang, Yuan Li Shen, Ann T Farrell, Richard Pazdur
On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (BV). Nivolumab in cHL had been granted breakthrough therapy designation. Accelerated approval was based on two single-arm, multicenter trials in adults with cHL. In 95 patients with relapsed or progressive cHL after autologous HSCT and post-transplantation BV, nivolumab, dosed at 3 mg/kg intravenously every 2 weeks, produced a 65% (95% confidence interval: 55%-75%) objective response rate (58% partial remission, 7% complete remission)...
April 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28438857/reduced-competitive-repopulation-capacity-of-multipotential-hematopoietic-stem-cells-in-the-bone-marrow-of-friend-virus-infected-fv2-resistant-mice
#8
Michael W Epperly, Xichen Zhang, Renee Fisher, Wen Hou, Darcy Franicola, Donna Shields, Michael Quickel, Pamela Hankey-Giblin, Hong Wang, Joel S Greenberger
BACKGROUND/AIM: The polycythemia form of Friend leukemia virus (FVP) causes splenomegaly and lethal erythroleukemia in Fv-2(s)-susceptible mouse strains. We sought to determine whether the hematopoietic stem cell (HSC) pool was expanded in Fv-2(r)-resistant mice. MATERIALS AND METHODS: The 120-day bone marrow transplantation competitive repopulation assay was used to determine whether FVP-infected Fv-2(r) C57BL/6 mice demonstrated expansion of the HSC pool compared to the pool of committed hematopoietic progenitor cells in the same marrow assayed in vitro...
May 2017: In Vivo
https://www.readbyqxmd.com/read/28434928/hypercvad-chemotherapy-in-mantle-cell-lymphoma-patients-is-associated-with-higher-rates-of-hematopoietic-progenitor-cell-mobilization-failure-despite-plerixafor-rescue
#9
Amandeep Salhotra, Yuan Shan, Ni-Chun Tsai, James F Sanchez, Ibrahim Aldoss, Haris Ali, Tanya Paris, Ricardo Spielberger, Thai M Cao, Auayporn Nademanee, Stephen J Forman, Robert Chen
Induction regimens for mantle cell lymphoma (MCL) can be categorized into highly intensive ones containing cytarabine and less intense regimens such as R (rituximab) CHOP or R-bendamustine. Prior publications have shown R-hyperCVAD can be associated with stem cell mobilization failures. However, those studies did not include the use of plerixafor as rescue for stem cell mobilization failure. We examined our database of 181 consecutive MCL patients from 2005 to 2015 who received upfront therapy with either R-hyperCVAD or less intense chemotherapy (R-bendamustine and R-CHOP only) regimens to assess impact of frontline chemotherapy on collection of hematopoietic cell progenitors prior to autologous stem cell transplant (ASCT)...
April 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28433882/hypothyroidism-following-allogeneic-hematopoietic-stem-cell-transplantation-for-acute-myeloid-leukemia
#10
Michael Medinger, Deborah Zeiter, Dominik Heim, Jörg Halter, Sabine Gerull, André Tichelli, Jakob Passweg, Nicole Nigro
BACKGROUND: Hypothyroidism may complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT); we therefore analyzed risk factors in this study. PATIENTS AND METHODS: We studied 229 patients with acute myeloid leukemia (AML) who underwent an allo-HSCT between 2003 and 2013 with different conditioning regimens (myeloablative, reduced-intensity, chemotherapy-based, or total body irradiation-based). Thyroid-stimulating hormone (TSH) and free thyroxine levels (fT4) were available in 104 patients before and after allo-HSCT...
April 13, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28432802/subsequent-malignancies-after-allogeneic-hematopoietic-stem-cell-transplantation
#11
Mehmet Gündüz, Mehmet Özen, Uğur Şahin, Selami Koçak Toprak, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Önder Arslan, Muhit Özcan, Taner Demirer, Meral Beksaç, Osman İlhan, Günhan Gürman, Pervin Topçuoğlu
We evaluated 979 patients for the development of post-transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo-HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo-HSCT to the development of PTLD was 9 (3-20) months and that from allo-HSCT to the development of solid tumors was 93 (6-316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1...
April 22, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28431019/identifying-cytomegalovirus-cmv-complications-using-the-quantiferon-cmv-assay-after-allogeneic-hematopoietic-stem-cell-transplantation
#12
Michelle K Yong, Paul U Cameron, Monica Slavin, C Orla Morrissey, Krystal Bergin, Andrew Spencer, David Ritchie, Allen C Cheng, Assia Samri, Guislaine Carcelain, Brigitte Autran, Sharon R Lewin
Background: Cytomegalovirus (CMV) reactivation and disease remain a major cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. A simple test to identify recovery of CMV-specific T-cell immunity could assist clinicians in managing CMV-related complications. Methods: In an observational multi-centre prospective study of 94 allogeneic HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9 and 12 months post-transplant using the Quantiferon-CMV®, an ELISpot assay and in a subset, we also evaluated intracellular cytokine staining (ICS)...
April 18, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28429246/comparison-of-efficacy-and-safety-of-caspofungin-versus-micafungin-in-pediatric-allogeneic-stem-cell-transplant-recipients-a-retrospective-analysis
#13
Natalia Maximova, Giulia Schillani, Roberto Simeone, Alessandra Maestro, Davide Zanon
INTRODUCTION: The high morbidity and mortality associated with invasive fungal infections (IFIs) provide the rationale for antifungal prophylaxis in immuno-compromised pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Caspofungin and micafungin are antifungal agents of interest for prophylaxis of IFIs because of their potency against Candida and minimal toxicity or interactions with other drugs. Few studies have demonstrated the safety and efficacy of such echinocandins as prophylaxis for IFIs in patients undergoing HSCT...
April 20, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28428936/multistate-models-on-pleural-effusion-after-allogeneic-hematopoietic-stem-cell-transplantation
#14
Joohyoung Lee, Dipenkumar Modi, Hyejeong Jang, Joseph P Uberti, Seongho Kim
A multistate model is more complicated than competing risk models and composed of finite number of states and transitions between states. Unlike competing risk models, this model has the ability to assess the effect of occurrence order of time-to-event data. Pleural effusion (PE) is a severe complication that often occurs after allogeneic hematopoietic stem cell transplantation (HSCT). Many patients develop pleural effusion during the first 100 days after allogeneic HSCT and graft-versus-host disease (GVHD) occurs either before or after the development of PE, implying that the occurrence order of PE and GVHD (i...
2017: Open Access Medical Statistics
https://www.readbyqxmd.com/read/28428885/the-why-what-and-how-of-the-new-fact-standards-for-immune-effector-cells
#15
EDITORIAL
Marcela V Maus, Sarah Nikiforow
Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Receptor (CAR) T cells, are poised for FDA approval and thus increased use at a wider range of academic centers within the next year, with the likelihood of dissemination to standard oncology practice once safety is confirmed...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28427505/toxicity-of-iron-overload-and-iron-overload-reduction-in-the-setting-of-hematopoietic-stem-cell-transplantation-for-hematologic-malignancies
#16
REVIEW
Heather A Leitch, Eitan Fibach, Eliezer Rachmilewitz
Iron is an essential element for key cellular metabolic processes. However, transfusional iron overload (IOL) may result in significant cellular toxicity. IOL occurs in transfusion dependent hematologic malignancies (HM), may lead to pathological clinical outcomes, and IOL reduction may improve outcomes. In hematopoietic stem cell transplantation (SCT) for HM, IOL may have clinical importance; endpoints examined regarding an impact of IOL and IOL reduction include transplant-related mortality, organ function, infection, relapse risk, and survival...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28427167/dynamic-changes-in-serum-cytokine-levels-and-their-clinical-significance-in-predicting-acute-gvhd
#17
Chunyan Zhang, Wenrong Huang, Pengjun Zhang, Qingyi Zhang, Guanghong Guo, Feng Gu, Hua Yang, Yurong Wang, Xueliang Huang, Qian Jia, Yaping Tian
To explore the clinical significance of cytokines and biochemical tests in acute graft-versus-host disease (aGVHD), we detected the concentrations of 8 cytokines and 19 conventional biochemical markers in the sera of aGVHD and non-GVHD patients throughout the process of allogeneic hematopoietic stem cell transplantation and the onset of aGVHD. Predictive models were then established using the 27 indices, and models were verified by a prospective trial. The 27 indices showed significant differences between aGVHD patients and non-GVHD control subjects (two-tailed p<0...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28424902/physical-and-psychosocial-aspects-of-adolescent-and-young-adults-after-allogeneic-hematopoietic-stem-cell-transplantation-results-from-a-prospective-multicenter-trial
#18
Kristin Pulewka, Daniel Wolff, Philipp Y Herzberg, Hildegard Greinix, Pia Heussner, Friederike H A Mumm, Stephanie von Harsdorf, Kathrin Rieger, Philipp Hemmati, Andreas Hochhaus, Inken Hilgendorf
PURPOSE: Allogeneic hematopoietic stem-cell transplantation (alloHSCT) is physically and psychosocially demanding. Among transplant recipients, adolescent and young adults (AYA) represent a special group, as disease occurs early in life, resulting in the prospect of long survival time and high burden of alloHSCT sequelae. However, data focusing on AYA undergoing alloHSCT are rare. METHODS: Data resulting from a prospective multicenter trial initially focusing on graft-versus-host disease (GvHD) after alloHSCT were reused to analyse the differences between AYA and elderly patients...
April 19, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28424633/psychopathological-aspects-in-childhood-hematopoietic-stem-cell-transplantation-hsct-the-perception-of-parents-and-adolescents
#19
Silvia Zanato, Annalisa Traverso, Marta Tremolada, Francesco Sinatora, Alessio Porreca, Giorgio Pozziani, Nicoletta Di Florio, Fabia Capello, Antonio Marzollo, Manuela Tumino, Chiara Cattelan, Giuseppe Basso, Chiara Messina
Background: Data about psychosocial sequelae of childhood Hematopoietic Stem Cell Transplantation (HSCT) are limited and the association with a specific donor type or other medical factors is largely unknown (Chang et al., 2012). The aim of the present study was to compare the psychological aspects of pediatric HSCT survivors with healthy peers. A secondary aim was to detect whether parents and children differed in the perception of mental health status. The influence of medical factors on psychological status was also examined...
2017: Frontiers in Psychology
https://www.readbyqxmd.com/read/28424554/arterial-stiffness-in-hematologic-malignancies
#20
REVIEW
Ioana Mozos, Georgiana Borzak, Alexandru Caraba, Rodica Mihaescu
Malignant and cardiovascular disorders are the top causes of mortality worldwide. This article reviews the main literature data and mechanisms linking hematologic malignancies and arterial stiffness, focusing on recent experimental and clinical results. Several links were found in hematologic malignancies between complete blood count and arterial stiffness. Chemotherapy, especially anthracyclines, cyclophosphamide and tyrosine kinase inhibitors, as well as radiotherapy and hematopoietic stem cell transplantation are the main known causes of arterial stiffness increase in hematologic malignancies...
2017: OncoTargets and Therapy
keyword
keyword
11336
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"